STOCK TITAN

Regeneron Pharmaceuticals - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.

Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.

All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the New England Journal of Medicine published positive Phase 3 trial results for evinacumab in patients with homozygous familial hypercholesterolemia (HoFH). This investigational drug significantly reduced LDL cholesterol levels by 49% when added to standard therapies, especially in patients with low or no LDL-receptor activity. Evinacumab is under FDA Priority Review, with a decision expected by February 11, 2021, addressing a critical need for effective treatment in HoFH patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
-
Rhea-AI Summary

On August 19, 2020, Regeneron and Roche announced a collaboration to develop, manufacture, and distribute REGN-COV2, Regeneron's antibody cocktail for COVID-19. This partnership aims to increase production capacity by over 350%, significantly boosting the availability of doses for patients both in the U.S. and globally. REGN-COV2 is currently undergoing Phase 2/3 trials for treatment and Phase 3 trials for prevention. The companies are committed to sharing distribution responsibilities, with Regeneron handling U.S. sales and Roche focusing on international markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
covid-19
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) announced the FDA's acceptance for Priority Review of its Biologics License Application (BLA) for evinacumab, targeting patients with homozygous familial hypercholesterolemia (HoFH). HoFH affects approximately 1,300 patients in the U.S., many of whom do not achieve optimal LDL-C levels with existing therapies. Evinacumab is designed to block angiopoietin-like 3 (ANGPTL3) to lower LDL-C. The FDA's target action date is February 11, 2021, and the drug has previously received Breakthrough Therapy designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals announced the pricing of its underwritten offering of $1.250 billion in senior unsecured notes due 2030 with a 1.750% interest rate, and $750 million in notes due 2050 with a 2.800% interest rate. The issuance is expected to close around August 12, 2020. The funds will be used primarily to repay outstanding loans related to a stock repurchase from Sanofi and for general corporate purposes. The offering will support Regeneron's financial stability as it continues its drug development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
-
Rhea-AI Summary

Regeneron Pharmaceuticals reported a 24% revenue increase to $1.95 billion in Q2 2020, driven by strong sales of EYLEA and Dupixent. EYLEA's U.S. net sales were $1.11 billion, while Dupixent's global sales reached $945 million. GAAP diluted EPS stood at $7.61. The company initiated Phase 2 and 3 trials for REGN-COV2, targeting COVID-19. It also received FDA approval for Dupixent in children aged 6-11 with atopic dermatitis. Regeneron's balance sheet remains robust, positioning it for long-term growth amid operational challenges presented by the pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
Rhea-AI Summary

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Society for Science & the Public announced winners of the Regeneron Science Talent Search 2020, awarding over $1.8 million in prizes to young innovators. Lillian Petersen won the top prize of $250,000 for her tool predicting crop yields, addressing food insecurity. Other notable projects included machine learning algorithms and eco-friendly industrial burners, showcasing youth contributions to science. The competition highlighted the importance of research in solving global challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) awarded $1.8 million to finalists of the 2020 Regeneron Science Talent Search, recognizing outstanding research by high school seniors. The top award of $250,000 went to Lillian Petersen from New Mexico for her tool predicting harvests, addressing food insecurity. Other notable projects include machine learning algorithms and eco-friendly gas burners. The competition, held virtually for the first time due to the pandemic, fosters scientific innovation among youth and has historically produced renowned science leaders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that BARDA has agreed to procure its investigational Ebola treatment, REGN-EB3, as part of national health emergency preparedness. REGN-EB3, currently under FDA Priority Review with a decision due by October 25, 2020, is expected to generate approximately $10 million in 2021 and an average of $67 million annually from 2022 to 2026 if approved. This follows promising results from the PALM trial, demonstrating superior efficacy in preventing Ebola-related deaths compared to existing treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
Rhea-AI Summary

Regeneron Pharmaceuticals (NASDAQ: REGN) will report its Q2 2020 financial and operating results on August 5, 2020, before U.S. markets open. A conference call and webcast will be held at 8:30 AM ET on the same day. Investors can access the call by dialing (888) 660-6127 (U.S.) or (973) 890-8355 (International). Regeneron is a biotechnology leader focused on inventing medicines for serious diseases, with a robust pipeline developed through their proprietary VelociSuite® technologies. For more information, visit www.regeneron.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
conferences
Regeneron Pharmaceuticals

Nasdaq:REGN

REGN Rankings

REGN Stock Data

60.05B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN